Companies › Upsher-Smith Laboratories
1 active drug program in 5 registered trials: 4 Phase 4, 1 Phase 2; Neurology, Metabolic and endocrine, Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Topiramate Carbonic anhydrase II inhibitor; Carbonic anhydrase IV inhibitor; Glutamate receptor ionotropic AMPA antagonist | CA2, CA4, GRIA4, GRIA3, GRIA2 | Phase 4 | Migraine Disorders; Obesity; Ménière; Liver Cirrhoses … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03667846 | Topiramate | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | Aug 2025 |
| NCT04748601 | Topiramate | Phase 4 | Migraine Disorders | Neurology | Sep 2026 |
| NCT05975580 | Topiramate | Phase 4 | Obesity | Metabolic and endocrine | Jul 2027 |
| NCT05582837 | Topiramate | Phase 4 | Ménière | Neurology | Dec 2027 |
| NCT07058155 | Topiramate | Phase 4 | Liver Cirrhoses | Metabolic and endocrine | Feb 2029 |
Neurocrine Biosciences Eisai Proniras Shionogi Tecnoquimicas Incannex Healthcare
Impax Laboratories IntraBio Zhejiang Hanmai Pharmaceutical Technology Sichuan Jishengtang Pharmaceutical Idorsia Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.